John after the raise earlier this year and as of 3-31-15 the company had 34,M cash with no debt. There is no cash raise pending today..unless someone wants to collaborate or buyin..as Jane said. I am a mind reader in my spare time. My opinion is that management felt that the raise this year was limited to continuing day to day with a healthy start on P3. Lets say they took a measured approach. I feel certain that the next raise will be on better terms for them and for the stockholders. My hot sports opinion. The update on P2 will tell all this fall. GLTA.
Ok..I can't find the article but it was a spin off of the Celgene/Juno partnership talking about the technology. Here is an article from street Insider from Nov 2014 about the Caltech agreement with IMUC. Needless to say if this tech sector finds favor as a viable technology then IMUC is a steal. GLTA..
Roth Capital affirms ImmunoCellular Therapeutics (AMEX: IMUC) at Buy with a price target of $3 following news that the company has licensed from the California Institute of Technology (Caltech) the exclusive rights to a novel technology to develop antigen specific killer T cells.
Analyst Joseph Pantginis commented, We believe this new initiative by IMUC into a new immunotherapy modality is a promising one as it expands its profile and capabilities to use the immune system to attach the tumor. The main advantage of the new licensed technology over other engineered T cell approaches such as chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies is the duration of their effects. CAR and TCR technologies are currently limited by the limited immune responses they elicit. Since this new technology uses stem cells, it has the potential to have a lasting immune activation as the pool of stem cells will supplement the depletion in the differentiated engineered T cells. Additionally, with this new T cell-based approach, IMUC could potentially combine their approaches. i.e., use of its dendritic cell technology that activates the immune system with antigen-specific T cells that target and destroy tumor cells. This sits in line with the company's stated goals of introducing new immunotherapy technologies that can expand and complement its current platform. We now look forward to updated survival data from the ICT-107 Phase II at SNO in November as well as the start of the Phase III following positive FDA feedback.
Catalyst pending..signing a patient registration deal with a couple of agencies that farm for patients, updated data from P2 in Oct or Nov. Intiation of P3 trial The biggest being the continued data improvement from P2..Plus there is always the possibility someone partners up. GLTA..there was an an article published yesterday pointing to this same technology as the next big thing in cancer treatment. I can't find it now..will look somemore.